Actinium Pharmaceuticals, Inc.(NYSE Amex Equities : ATNM)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | 0.01% | 90.69 | 1.3% | $857.92m | |
| AMGN | Amgen Inc. | 0.89% | 188.34 | 1.2% | $633.58m | |
| GILD | Gilead Sciences, Inc. | 1.84% | 67.59 | 0.9% | $514.47m | |
| BIIB | Biogen Inc. | 2.51% | 332.87 | 1.3% | $435.40m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.17% | 423.97 | 2.6% | $309.18m | |
| ILMN | Illumina, Inc. | 2.51% | 299.82 | 3.5% | $302.75m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 1.27% | 188.07 | 1.9% | $286.68m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 2.77% | 129.42 | 2.0% | $247.61m | |
| A | Agilent Technologies, Inc. | 1.64% | 78.28 | 1.6% | $135.81m | |
| INCY | Incyte Corporation | 0.88% | 84.15 | 2.5% | $133.07m | |
| ALNY | Alnylam Pharmaceuticals, Inc | 0.60% | 83.53 | 9.2% | $82.59m | |
| BLUE | Bluebird Bio, Inc. | 2.04% | 137.03 | 14.4% | $74.39m | |
| SGEN | Seattle Genetics, Inc. | 4.24% | 71.48 | 6.6% | $67.96m | |
| NKTR | Nektar Therapeutics | -2.18% | 41.69 | 5.5% | $65.74m | |
| TECH | Bio-Techne Corporation | 1.63% | 191.63 | 4.7% | $48.41m |
Company Profile
Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.